Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3156067 | 0.89 | THRA (0.72) | THRATHRB | |
| SCHEMBL4962867 | 0.87 | THRA (0.69) | THRATHRB | |
| SCHEMBL21127688 | 0.86 | THRA (0.68) | THRATHRB | |
| SCHEMBL4962653 | 0.85 | THRB (0.63) | THRATHRB | |
| SCHEMBL7073346 | 0.84 | THRA (0.73) | THRATHRB | |
| SCHEMBL7074654 | 0.84 | THRA (0.73) | THRATHRB | |
| SCHEMBL5619285 | 0.83 | THRA (1.00) | THRATHRB | |
| SCHEMBL7069926 | 0.83 | THRA (0.71) | THRATHRB | |
| SCHEMBL5618672 | 0.82 | THRA (0.73) | THRATHRB | |
| SCHEMBL5619222 | 0.81 | THRA (0.77) | THRATHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8946224-B2 | Substituted [1,2,4]triazolo[4,3-A]pyrazines for medicaments and pharmaceutical compositions | REDX PHARMA LIMITED (GB) | 2015-02-03 | — | — | US | disclosed |
| US-8946224-B2 | Substituted [1,2,4]triazolo[4,3-A]pyrazines for medicaments and pharmaceutical compositions | REDX PHARMA LIMITED (GB) | 2015-02-03 | — | — | US | disclosed |
| US-20130225594-A1 | DRUG DERIVATIVES | REDX PHARMA PLC (GB) | 2013-08-29 | — | — | US | disclosed |
| US-20130225594-A1 | DRUG DERIVATIVES | REDX PHARMA PLC (GB) | 2013-08-29 | — | — | US | disclosed |
| WO-2012063085-A2 | DRUG DERIVATIVES | REDX PHARMA LIMITED (GB) | 2012-05-18 | — | — | WO | disclosed |
| US-7956214-B2 | Process for the preparation of aniline-derived thyroid receptor ligands | KARO BIO AB (SE) | 2011-06-07 | — | — | US | disclosed |
| US-20090326263-A1 | Process for the preparation of aniline-derived thyroid receptor ligands | CHIDAMBARAM RAMAKRISHNAN | 2009-12-31 | — | — | US | disclosed |
| US-20050054873-A1 | Process for the preparation of aniline-derived thyroid receptor ligands | KARO BIO AB (SE) | 2005-03-10 | — | — | US | disclosed |
| US-6806381-B2 | SUCH AS N-(3,5-DIBROMO-4-(4-HYDROXY-3-ISOPROPYL-PHENOXY)-PHENYL)-MALONAMIC ACID; FOR TREATMENT OF THYROID DISORDERS | BRISTOL-MYERS SQUIBB COMPANY | 2004-10-19 | — | — | US | disclosed |
| US-20030157671-A1 | Process for the preparation of aniline-derived thyroid receptor ligands | KARO BIO AB (SE) | 2003-08-21 | — | — | US | disclosed |
| WO-2003039456-A2 | PROCESS FOR THE PREPARATION OF ANILINE-DERIVED THYROID RECEPTOR LIGANDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-05-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130225594-A1 | DRUG DERIVATIVES | SQOR, NQO1, CYP2D6 | THRA 4639/4885THRB 4410/4885 |
| US-20050054873-A1 | Process for the preparation of aniline-derived thyroid receptor ligands | TSHR, THRA, THRB | THRA 2/4885THRB 3/4885 |
| US-20090326263-A1 | Process for the preparation of aniline-derived thyroid receptor ligands | TSHR, THRA, THRB | THRA 2/4885THRB 3/4885 |
| US-20030157671-A1 | Process for the preparation of aniline-derived thyroid receptor ligands | TSHR, THRA, THRB | THRA 2/4885THRB 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.